Dapagliflozin in Myocardial Infarction Without Diabetes or Heart Failure (DAPA-MI)
Source: View publication →
The DAPA-MI trial demonstrated that, in patients without diabetes or chronic heart failure following an acute myocardial infarction, dapagliflozin significantly improved a hierarchical composite of cardiometabolic outcomes compared to placebo, largely driven by reduced new-onset diabetes and weight loss, though with no difference in cardiovascular death or heart failure hospitalizations.
Key Findings
Study Design
Study Limitations
Clinical Significance
The trial suggests that initiating dapagliflozin shortly after an acute MI in patients without diabetes may offer cardiometabolic benefits, such as preventing new-onset diabetes and promoting weight loss, which are favorable in a secondary prevention context. However, it does not support the routine use of dapagliflozin in this specific population for the sole purpose of reducing cardiovascular mortality or heart failure hospitalizations.
Historical Context
Sodium-glucose cotransporter-2 (SGLT2) inhibitors established themselves as transformative therapies for heart failure and chronic kidney disease in patients with and without diabetes. DAPA-MI sought to extend this therapeutic evidence base to the acute myocardial infarction setting, shifting focus toward early intervention in a lower-risk population to see if metabolic gains could translate to long-term cardiovascular stability.
Guided Discussion
High-yield insights from every perspective
What is the primary physiological mechanism of sodium-glucose cotransporter 2 (SGLT2) inhibitors that extends their utility to patients without diabetes, particularly in the post-myocardial infarction setting?
Key Response
SGLT2 inhibitors promote natriuresis and osmotic diuresis, which reduces preload and afterload. Beyond glucose lowering, they shift myocardial metabolism toward more efficient ketone body oxidation, reduce oxidative stress, and decrease sympathetic activity, all of which support favorable left ventricular remodeling and decrease the risk of heart failure even in euglycemic patients.
In a patient who has just suffered an acute MI but has no history of diabetes or heart failure (LVEF > 40%), what specific benefits does the DAPA-MI trial suggest for initiating dapagliflozin prior to discharge?
Key Response
DAPA-MI showed that dapagliflozin significantly improved a hierarchical composite outcome (win ratio) primarily driven by cardiometabolic benefits, including weight loss and a reduction in new-onset diabetes. However, unlike trials in patients with established heart failure or diabetes, it did not significantly reduce the individual risks of cardiovascular death or heart failure hospitalization in this specific low-risk population.
The DAPA-MI trial utilized a 'win ratio' approach for its primary endpoint. How does the inclusion of 'softer' endpoints like weight loss and new-onset diabetes in this hierarchical model complicate the interpretation of dapagliflozin's efficacy in preventing major adverse cardiovascular events (MACE) post-MI?
Key Response
The win ratio prioritizes hard outcomes (death, HFH) but allows the trial to gain power from more frequent outcomes (weight change, HbA1c). In DAPA-MI, the 'win' was almost entirely due to metabolic parameters. For a fellow, this necessitates a nuanced discussion with patients: the drug is a potent cardiometabolic stabilizer, but the trial was likely underpowered or the population too low-risk to demonstrate the mortality/morbidity benefits seen in the DAPA-HF or EMPA-KIDNEY cohorts.
Given the results of DAPA-MI and the concurrent EMPACT-MI trial, how should we balance the 'early and often' philosophy of SGLT2i initiation against the lack of significant reduction in hard cardiovascular endpoints in the acute post-MI period for patients without baseline HF or DM?
Key Response
The DAPA-MI trial suggests that while safe and metabolically beneficial, the immediate post-MI initiation of SGLT2i in patients without HF or DM does not carry the same 'life-saving' urgency as it does in HFrEF. Practitioners should view SGLT2i in this cohort as a strategy for long-term metabolic health and primary prevention of diabetes rather than an acute intervention for reducing 12-month CV mortality.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of a hierarchical win ratio in DAPA-MI from a statistical power perspective. What are the implications of the 'win' being driven by the lowest tier of the hierarchy (weight loss/diabetes) when the higher-tier components (CV death) showed no significant difference?
Key Response
The win ratio can be sensitive to the ordering and the frequency of events. Since weight loss and HbA1c changes occur in nearly every participant, they dominate the win ratio calculation once the rare occurrences of death or HFH are accounted for. This can result in a statistically significant 'win' that may not reflect a clinically meaningful shift in the primary disease process (infarction-induced HF), necessitating sensitivity analyses that exclude the 'soft' tiers to confirm robustness.
DAPA-MI moved from a traditional MACE endpoint to a hierarchical composite win ratio during the course of the study. As a reviewer, what concerns would you raise regarding 'mid-stream' changes to primary endpoints and the potential for 'p-hacking' or result optimization?
Key Response
Changing a primary endpoint after the start of a trial (even if blinded) often triggers concerns about statistical opportunistic behavior. An editor would demand rigorous proof that the change was made without knowledge of the accumulating data and would likely flag the discrepancy between the 'positive' composite and the 'negative' components of CV death and HFH, questioning if the trial's 'positive' label is somewhat misleading regarding hard clinical outcomes.
Should current ACS guidelines (e.g., ACC/AHA or ESC) be updated to include a Class I recommendation for SGLT2 inhibitors in all post-MI patients regardless of LVEF or glycemic status, or does DAPA-MI support a more conservative Class IIb recommendation?
Key Response
Current guidelines (like the 2023 ESC Guidelines for ACS) strongly recommend SGLT2i for patients with DM or HFrEF (Class I). DAPA-MI provides evidence for cardiometabolic benefit but fails to show a reduction in CV death or HFH in those without these conditions. Therefore, a Class I recommendation is unlikely; a Class IIa or IIb recommendation for 'reduction of cardiometabolic risk' is more appropriate, emphasizing that the benefit is primarily metabolic rather than a reduction in immediate post-ischemic structural failure.
Clinical Landscape
Noteworthy Related Trials
EMPA-REG OUTCOME
Tested
Empagliflozin 10/25mg daily
Population
T2DM patients with high cardiovascular risk
Comparator
Placebo
Endpoint
3-point MACE
DAPA-HF Trial
Tested
Dapagliflozin 10mg daily
Population
Patients with HFrEF
Comparator
Placebo
Endpoint
Composite of worsening heart failure or cardiovascular death
EMMI Trial
Tested
Empagliflozin 10mg daily
Population
Patients with acute myocardial infarction
Comparator
Placebo
Endpoint
Change in left ventricular end-systolic volume index
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis